Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738569 · ClinicalTrials.gov registry record · NA
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
A NA study, sponsored by National Jewish Health.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00738569 is a NA study that has completed, run by National Jewish Health. The registered enrollment target is 30 participants.
The verdict
NCT00738569, a NA study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether or not adding Raltegravir to a fully suppressive antiretroviral regimen will assist in reducing HIV-1 associated chronic inflammation and increase the t-lymphocyte memory cell pool.
Interventions
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00738569
The ClinicalTrials.gov registry entry for NCT00738569 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Raltegravir is the first listed.
NCT00738569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00738569 about?
NCT00738569 is a clinical study titled "Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen". The purpose of this study is to determine whether or not adding Raltegravir to a fully suppressive antiretroviral regimen will assist in reducing HIV-1 associated chronic inflammation and increase the t-lymphocyte memory cell pool.
What is the current status of trial NCT00738569?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2008-07. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00738569?
The interventions under investigation include: Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00738569?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.